Navigation Links
MMV develops framework to assess risk of resistance for antimalarial compounds
Date:8/22/2012

Medicines for Malaria Venture has developed a framework to evaluate the risk of resistance for the antimalarial compounds in its portfolio. A paper based on this work: A framework for assessing the risk of resistance for antimalarials in development has been published in the Malaria Journal today.

Resistance defines the longevity of every anti-infective drug, so it is important when developing new medicines for malaria, to check how easily promising antimalarial compounds will select for resistance. Once this is known, it facilitates the prioritization of not only the most efficacious compounds but also the most robust ones.

"By profiling our portfolio as early as possible in terms of resistance liabilities, be they pre-existing or acquired, we are attempting to ensure that none of the compounds will fall to potential resistance," said Tim Wells, Chief Scientific Officer, MMV, and one of the authors of the paper. "This will also help us cost-effectively accelerate the drug development process, and be prepared in advance with a full resistance profile which is required by regulatory authorities before a new drug can be approved."

A cross-resistance test using a panel of multi-drug resistant strains of the parasite will check for pre-existing resistance liability. This will ensure that none of MMV's compounds are cross-resistant with other drugs, e.g., if a parasite is resistant to chloroquine, its resistance will also be profiled against MMV compounds.

The framework also includes selection experiments in the laboratory that measure how easy it is for the parasite to develop resistance, in other words, the likelihood of the occurrence of mutations that confer resistance. This is achieved by measuring the minimal inoculum for resistance (MIR) the minimum number of parasites from which a resistant one is likely to be selected by drug pressure. Although this is already being done, the framework offers a standard, systemat
'/>"/>

Contact: Jaya Banerji
banerjij@mmv.org
41-022-799-4071
Medicines for Malaria Venture
Source:Eurekalert

Page: 1 2

Related biology news :

1. US-Russian collaboration develops new method for sequencing dark matter of life from a single cell
2. University of Illinois professor develops tool that helps dietitians deliver info clients need and can understand
3. Pitt develops biodegradable artery graft to enhance bypass surgeries
4. MindSpec develops Autism Quiz app
5. Geneticist develops tool to identify genes important in disease, tailoring individual treatment
6. Pod corn develops leaves in the inflorescences
7. Genetic research develops tools for studying diseases, improving regenerative treatment
8. Diabetes Research Institute develops oxygen-generating biomaterial
9. Novo Nordisk and BGI establish global collaboration framework
10. Triage for plants: NYBG scientists develop and test rapid species conservation assessment technique
11. UCLA research makes possible rapid assessment of plant drought tolerance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... major interest in neuroscience. A large number of ... of Wallerian degeneration: transcription factor activation, immune response, ... responses in the distal segment of the sciatic ... in gene expression between the proximal and distal ... from Nantong University, China used microarrays to analyze ...
(Date:7/30/2014)... robust therapies for spinal cord injury (SCI), traumatic brain ... A great deal has been learned over the past ... environmental factors that regulate axon growth, but this large ... available therapeutics. Prof. Lemmon and his team from University ... many root causes, but a consensus is emerging that ...
(Date:7/30/2014)... roughly 3,000 pieces is still in its infant stage. ... be of major significance. "Amazingly often, we are findingin ... amber that we found in Baltic amber," explained Bonn ... amber comes from the Baltic Sea region, which is ... are, e.g., the coastal regions of Mecklenburg, Poland and ...
Breaking Biology News(10 mins):Chinese mosquitos on the Baltic Sea 2
... with the heat insulation of leaf litter and soil can ... helping land managers find the best time to use prescribed ... "Acorns inside the leaf litter or in the soil ... Greenberg, Forest Service Southern Research Station (SRS) researcher and lead ...
... Ore. Climate change, habitat destruction, pollution and invasive ... amphibian declines and extinctions, researchers suggest in a new ... in the form of infectious disease. Amphibians are ... range of infectious organisms, including viruses, bacteria and fungi, ...
... from the University of Southampton, which examines how dolphins might ... man-made sonar to detect targets, such as sea mines, in ... to blow ,bubble nets, around schools of fish, which force ... dolphins to pick off. However, such bubble nets would confound ...
Cached Biology News:Leaf litter and soil protect acorns from prescribed fire 2Environmental concerns increasing infectious disease in amphibians, other animals 2Do dolphins think nonlinearly? 2Do dolphins think nonlinearly? 3
(Date:7/30/2014)... Wellesley, MA (PRWEB) July 30, 2014 ... report, Global Markets for Enzymes in Industrial Applications ... to reach to nearly $7.1 billion by 2018, registering ... Maximum growth is estimated to be recorded in the ... the forecast period. , Enzyme technology has influenced almost ...
(Date:7/30/2014)... Md. , July 30, 2014 ... components to interrogate biology, but such devices can ... As such, researchers have looked ... in vitro metabolic engineering to characterize ... a chip. New devices are envisioned to recreate ...
(Date:7/30/2014)... July 30, 2014 Connecticut Center for ... based in East Hartford, Conn., was awarded a Rural ... of a project that will determine the feasibility of ... north-central Connecticut. USDA Rural Development provided $53,000 for CCAT ... the second phase of the feasibility study in fiscal ...
(Date:7/29/2014)... 30, 2014 SoundConnect , ... company, is proud to announce the strategic additions ... in their Boston, Charleston and Atlanta offices. ... increased demand for hosted solutions, collaboration and mobility ... reduce cost. , SoundConnect was founded in 2004, ...
Breaking Biology Technology:Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 2Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 2UMD Researchers Bridge Gap between Microelectronics, Biological Systems 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 4USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 2USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 3SoundConnect Organization and Culture is Evolving 2
... LAIYANG, China, Feb. 17 /PRNewswire-Asia-FirstCall/ -- Genesis,Pharmaceuticals Enterprises, Inc. ... pharmaceutical company with its principal operations in the,People,s Republic ... quarter of its fiscal year 2009 ended December 31, ... Fiscal Year 2009 Highlights, -- Revenue ...
... in the Biotech IndustryFT. LAUDERDALE, Fla., Feb. ... full-service securities broker-dealer and investment bank, is ... Newbridge BioVentures Division ("NBV"). NBV is dedicated ... biotech industry and related investment opportunities for ...
... 17 Human Genome Sciences, Inc. (Nasdaq: ... GSK ) has initiated a Phase 3 clinical trial ... Syncria (R) (albiglutide) in the long-term treatment of ... will receive a $9 million milestone payment in the ...
Cached Biology Technology:Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 2Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 3Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 4Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 5Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 6Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 7Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 8Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 9Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 10Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 11Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 12Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 13Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 14Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 15Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 16Newbridge Securities Corporation Forms BioVentures Division 2Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes 2Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes 3Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes 4
Human Serpin B5/Maspin Affinity Purified Polyclonal Ab...
... S.J. Allen (1995) This book ... authorities on current issues relating to the ... major advances have been made recently which ... Topics include molecular neuropathology through clinical and ...
Normal human serum, single donor...
Cytidine 5'-Triphosphate, Sodium (CTP), 1 g. Category: Nucleotides & Enzymes & Biochemicals, Nucleotides, Additional Nucleotide Products....
Biology Products: